南方科技大学知识苑(SUSTech KC): Calcyclin-binding protein contributes to cholangiocarcinoma progression by inhibiting ubiquitination of MCM2

题名	Calcyclin-binding protein contributes to cholangiocarcinoma progression by inhibiting ubiquitination of MCM2
作者	Zhang, Yusen 1,2,3; Liu, Liping 1,2,3; Luo, Biwei 1,2,3; Tang, Honggui 1,2,3; Yu, Xiaofang 1,2,3; Bao, Shiyun 1,2,3
通讯作者	Bao, Shiyun
发表日期	2023
DOI	10.32604/or.2023.028418
发表期刊	ONCOLOGY RESEARCH 影响因子和分区
ISSN	0965-0407
EISSN	1555-3906
卷号	31 期号:3
摘要	Background: Cholangiocarcinoma (CCA) represents the epithelial cell cancer with high aggressiveness whose five-year survival rate is poor with standard treatment. Calcyclin-binding protein (CACYBP) shows aberrant expression within several malignant tumors, but the role of CACYBP in CCA remains unknown. Methods: Immunohistochemical (IHC) analysis was used to identify CACYBP overexpression in clinical samples of CCA patients. Moreover, its correlation with clinical outcome was revealed. Furthermore, CACYBP's effect on CCA cell growth and invasion was investigated in vitro and in vivo using loss-of-function experiments. Results: CACYBP showed up-regulation in CCA, which predicts the dismal prognostic outcome. CACYBP had an important effect on in-vitro and in-vivo cancer cell proliferation and migration. Additionally, knockdown of CACYBP weakened protein stability by promoting ubiquitination of MCM2. Accordingly, MCM2 up-regulation partly reversed CACYBP deficiency's inhibition against cancer cell viability and invasion. Thus, MCM2 might drive CCA development by Wnt/beta-catenin pathway. Conclusions: CACYBP exerted a tumor-promoting role in CCA by suppressing ubiquitination of MCM2 and activating Wnt/beta-catenin pathway, hence revealing that it may be the possible therapeutic target for CCA treatment.
相关链接	[来源记录]
收录类别	SCI
语种	英语
学校署名	通讯
资助项目	Shenzhen Key Medical Discipline Construction Fund[SZXK015] ; Guangdong Medical Science and Technology Research Fund[A2021230]
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:001015599900001
出版者	TECH SCIENCE PRESS
ESI学科分类	CLINICAL MEDICINE
来源库	Web of Science
引用统计	被引频次[WOS]：3
成果类型	期刊论文
条目标识符	http://sustech.caswiz.com/handle/2SGJ60CL/549362
专题	南方科技大学第一附属医院
作者单位	1.Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Dept Hepatobiliary & Pancrease Surg, Shenzhen 518020, Peoples R China 2.Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Dept Gen Surg, Shenzhen 518020, Peoples R China 3.Southern Univ Sci & Technol, Affiliated Hosp 1, Dept Hepatobiliary & Pancrease Surg, Shenzhen 518020, Peoples R China
第一作者单位	南方科技大学第一附属医院
通讯作者单位	南方科技大学第一附属医院
推荐引用方式 GB/T 7714	Zhang, Yusen,Liu, Liping,Luo, Biwei,et al. Calcyclin-binding protein contributes to cholangiocarcinoma progression by inhibiting ubiquitination of MCM2[J]. ONCOLOGY RESEARCH,2023,31(3).
APA	Zhang, Yusen,Liu, Liping,Luo, Biwei,Tang, Honggui,Yu, Xiaofang,&Bao, Shiyun.(2023).Calcyclin-binding protein contributes to cholangiocarcinoma progression by inhibiting ubiquitination of MCM2.ONCOLOGY RESEARCH,31(3).
MLA	Zhang, Yusen,et al."Calcyclin-binding protein contributes to cholangiocarcinoma progression by inhibiting ubiquitination of MCM2".ONCOLOGY RESEARCH 31.3(2023).